Research Papers:

The antitumor effect of arsenic trioxide on hepatocellular carcinoma is enhanced by andrographolide

Xuhua Duan, Tengfei Li, Xinwei Han _, Jianzhuang Ren, Pengfei Chen, Hao Li and Shaojun Gong

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:90905-90915. https://doi.org/10.18632/oncotarget.18677

Metrics: PDF 1478 views  |   HTML 1913 views  |   ?  


Xuhua Duan1,*, Tengfei Li1,*, Xinwei Han1,#, Jianzhuang Ren1,#, Pengfei Chen1, Hao Li1 and Shaojun Gong1

1Department of Interventional Radiology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan Province, People’s Republic of China

*These authors contributed equally to this work and share co-first authorship

#These authors contributed equally to this work

Correspondence to:

Xinwei Han, email: [email protected]

Jianzhuang Ren, email: [email protected]

Keywords: andrographolide, As2O3, HepG2 cells, apoptosis, EphB4

Received: February 14, 2017     Accepted: June 02, 2017     Published: June 27, 2017


High concentrations of arsenic trioxide (As2O3) are used to treat acute promyelocytic leukemia and solid tumors, with negative side effects to normal cells. Andrographolide is a traditional Chinese medicine that exerts anti-cancer, anti-inflammatory, anti-virus, and anti-diabetic effects. Here, we tested the effects of combined andrographolide with As2O3 against hepatocellular carcinoma (HCC). We found that by increasing apoptosis, andrographolide synergistically enhanced the anti-tumor effects of As2O3 in HepG2 cells in vitro and in vivo. Furthermore, results from our microarray assays and experiments with mouse xenografts showed that EphB4 was downregulated by the combination of As2O3 plus andrographolide. These findings suggest that the combination of andrographolide and As2O3 could yield therapeutic benefits in the treatment of HCC.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18677